T. Rowe Price Associates
FRTX

T. Rowe Price Associates’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

T. Rowe Price Associates’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,488
Closed -$14.7M – 2480
2013
Q2 		$14.7M Buy
+1,488
New +$16.5M ﹤0.01% 1159

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Litespeed Management New York $48.2M AUM 9.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

T. Rowe Price Associates's FRTX Position: Q3 2013 in Review

T. Rowe Price Associates sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2013, closing a stake of 1,488 shares — an estimated $14.7M sold.

T. Rowe Price Associates first reported a position in FRTX in Q2 2013 and held it in 1 quarter. The position peaked at $14.7M in Q2 2013. 83 funds tracked by Wall St. Rank hold FRTX as of Q3 2013.

  • T. Rowe Price Associates reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,488 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2013, an estimated $14.7M.
  • T. Rowe Price Associates first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • T. Rowe Price Associates's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $14.7M in Q2 2013.
  • 83 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2013.

Based on T. Rowe Price Associates's 13F filing for Q3 2013, filed 14 Nov 2013.